{"id":80676,"date":"2025-05-07T02:10:13","date_gmt":"2025-05-07T02:10:13","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/80676\/"},"modified":"2025-05-07T02:10:13","modified_gmt":"2025-05-07T02:10:13","slug":"novo-nordisk-on-the-back-foot-ahead-of-earnings-the-irish-times","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/80676\/","title":{"rendered":"Novo Nordisk on the back foot ahead of earnings \u2013 The Irish Times"},"content":{"rendered":"<p class=\"c-paragraph\">Novo Nordisk reports earnings on Wednesday, and for once, Wall Street isn\u2019t holding its breath. Once celebrated for routinely raising guidance, the Danish drugmaker is on the defensive. <\/p>\n<p class=\"c-paragraph paywall\">No longer Europe\u2019s most valuable company, shares have almost halved since early December, dragged down by disappointing trial data, intensifying competition from Eli Lilly, and growing doubts over Novo\u2019s ability to defend its position in the GLP-1 obesity drug market.<\/p>\n<p class=\"c-paragraph paywall\">Zepbound, Lilly\u2019s obesity drug, has overtaken Novo\u2019s equivalent, Wegovy, in the US and now commands over 50 per cent of the market. <\/p>\n<p class=\"c-paragraph paywall\">Novo had the early lead but its first-mover advantage has waned, undone by Lilly\u2019s superior supply chain, faster rollout of telehealth partnerships, and promising oral pipeline.<\/p>\n<p class=\"c-paragraph paywall\">Analysts have likened it to the story of the tortoise and the hare, but Lilly is not having it all its own way. <\/p>\n<p class=\"c-paragraph paywall\">Shares sank following Lilly\u2019s own earnings report on Thursday, with better-than-expected earnings overshadowed by news of a partnership between Novo and US healthcare giant CVS Health.<\/p>\n<p class=\"c-paragraph paywall\">Tuesday\u2019s results won\u2019t decide the race \u2013 but for Novo, another stumble could make the finish line feel even further away.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk reports earnings on Wednesday, and for once, Wall Street isn\u2019t holding its breath. Once celebrated for&hellip;\n","protected":false},"author":2,"featured_media":80677,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4316],"tags":[105,4348,5834,16,15],"class_list":{"0":"post-80676","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-health","9":"tag-healthcare","10":"tag-novo-nordisk","11":"tag-uk","12":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114464124045069236","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/80676","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=80676"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/80676\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/80677"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=80676"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=80676"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=80676"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}